GERD, Dyspepsia and Barrett’s Esophagus: Treatment Updates for 2025

Peter Buch, MD, AGAF, FACP Related seminars and products

Peter Buch, MD, AGAF, FACP, is a double board-certified clinical gastroenterologist with 35 years of experience, leads a team that treats all GI conditions, sits on editorial boards for numerous professional journals, is a highly sought-after international presenter, and hosts ReachMD GI Insights, a podcast that highlights the latest developments in gastroenterology. 
 

Dr. Buch has a passion for teaching. His style is case-based, practical, interactive, and evidence supported. Dr. Buch’s expertise has been shared with experienced clinicians and advanced-level students. He teaches at the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, and the Frank H Netter School of Medicine/Quinnipiac University. 

Speaker Disclosures:
Financial: Dr. Peter S. Buch has employment relationships with the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, and the Frank H Netter, MD School of Medicine. He receives compensation as a professional speaker and is a podcast host with ReachMD/GI Insight. Dr. Buch receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Peter S. Buch serves on the FDA and Patient Care Committees at the American College of Gastroenterology. He serves as an editor of peer-reviewed journals. He is a member of the International Association of Medical Science Educators, the AGA Academy of Educators, the American Gastroenterological Association (AGAF), the American College of Physicians (FACP), the Hartford County Medical Association, the American College of Gastroenterology (FACG), and the Connecticut State Medical Society.

Content Disclosure:

Dr. Buch references the use of antidepressants for Irritable Bowel Syndrome, and the controversial use of Fibrotest to evaluate patients with fatty liver disease who may have fibrosis of the liver. Dr. Buch indicates he wishes to present a fair and balanced approach to practitioners regarding such practices.